Navigation Links
Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org
Date:7/29/2014

Dallas, Texas (PRWEB) July 30, 2014

“PharmaSphere: Emerging Biotech Investment Report Strategic Trends in Private Equity and Venture Capital Funding” report provides in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry, bearing in mind that these are expected to have significant impact on the future of emerging biotechnology companies in the US and globally. Furthermore, the report identifies regions of the world that are attracting more investments in healthcare and discusses the various factors responsible for this trend. In addition, the report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013.

Order a Purchase copy @ http://www.marketoptimizer.org/contacts/purchase?rname=5634 .

Private Equity Firms: Company Drill-Downs:

  •     TPG Capital
  •     The Carlyle Group
  •     The Blackstone Group
  •     Kohlberg Kravis Roberts
  •     Warburg Pincus
  •     Goldman Sachs Principal Investment Area
  •     Advent International Corporation
  •     Apollo Global Management
  •     Bain Capital
  •     CVC Capital Partners
  •     Oaktree Capital Management
  •     Hellman & Friedman

Venture Capital Firms: Company Drill-Downs:

  •     New Enterprise Associates
  •     OrbiMed Advisor
  •     Canaan Partners
  •     Versant Ventures
  •     New Leaf Venture Partners
  •     Third Rock Ventures
  •     Domain Associates
  •     Kleiner Perkins Caufield & Byers
  •     Clarus Ventures
  •     Flagship Ventures

Key Questions Answered

  •     What are the current trends impacting emerging biotechnology investment in the US and globally?
  •     What regions are witnessing noteworthy investment in healthcare and what are the factors driving such occurrences?
  •     What therapeutic areas are attracting the most investment by private equity and venture capital firms and why?
  •     What has been the trend of equity offerings in the healthcare sector since 2004 and what factors were responsible?
  •     What is the strategic outlook of emerging biotechnology investment?

Complete Report Details @ http://www.marketoptimizer.org/pharmasphere-emerging-biotech-investment-report-strategic-trends-in-private-equity-and-venture-capital-funding.html .

This report is an essential source of information and analysis on emerging biotech investment, with significant emphasis on the US. GlobalData provides an in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry. The report highlights the various therapeutic areas attracting noteworthy funding in terms of the volume and value of new and follow-on investments and discusses the factors responsible for this trend. Furthermore, it provides a strategic outlook on future trends that are expected in private equity and venture capital funding and how they will impact the growth and development of biotech companies globally.

Major Points from Table of Content:

3 US Private Equity and Venture Capital Industry Dynamics 21
3.1 Post-2008 Financial Market Crash: Volume of Capital Commitments to Private Equity Funds Show Signs of Recovery 21
3.2 Volume over Value: Decrease in the Average Value of Completed Private Equity Healthcare Deals between 2007 and 2013 24
3.3 Healthcare Reform and Cost Pressures in Europe and North America Shifts Deal Activity to the Asia-Pacific Region 25
3.4 Private Equity Deals by Therapy Area 28
3.5 Private Equity Buyouts of 2013 30
3.6 Venture Capital Investment Trend 31
3.7 Venture Capital Investment: Biotechnology Plays Second Fiddle to Software 34
3.8 Seed-Stage Financing Shows Downward Trend 37
3.9 Venture-Backed Exits in 2013 38
3.10 California, Massachusetts, and New York Lead the Pack in Venture Capital Investment for 2013 42

4 Equity Offerings 44
4.1 Equity Offerings in the Healthcare Sector 44
4.2 Venture-Backed Initial Public Offerings in 2013 45
4.3 Venture-Backed Emerging Biotech Initial Public Offerings in 2013 46
4.4 Liquidity Position Makes Emerging Biotechs an Attractive Prospect for Investors 47
4.5 Company Profiles and Initial Public Offer Details 49
4.5.1 Intrexon Corporation (Stock Symbol: XON) 49
4.5.2 Ophthotech Corporation (Stock Symbol: OPHT) 51
4.5.3 PTC Therapeutics (Stock Symbol: PTCT) 52
4.5.4 Portola Pharmaceuticals (Stock Symbol: PTLA) 54
4.5.5 Agios Pharmaceuticals (Stock Symbol: AGIO) 55
4.5.6 Chimerix (Stock Symbol: CMRX) 57
4.5.7 Bluebird Bio (Stock Symbol: BLUE) 58
4.5.8 Foundation Medicine (Stock Symbol: FMI) 59
4.5.9 OncoMed Pharmaceuticals (Stock Symbol: OMED) 60
4.5.10 Acceleron Pharma (Stock Symbol: XLRN) 62
4.5.11 Prosensa Therapeutics (Stock Symbol: RNA) 64
4.5.12 Epizyme (Stock Symbol: EPZM) 65
4.5.13 Onconova Therapeutics (Stock Symbol: ONTX) 66
4.5.14 Tetraphase Pharmaceuticals (Stock Symbol: TTPH) 68
4.5.15 Esperion Therapeutics (Stock Symbol: ESPR) 69

Explore more reports on Biotechnology industry at http://www.marketoptimizer.org/category/life-sciences/biotechnology .

About Us:
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/biotech-investment-trends/private-equity-funding/prweb12054806.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
2. OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center
3. SURPASS Announces Two Strategic Hires in Silicon Valley Facility and Launch of Social Media Accounts
4. Strides Arcolab makes strategic investment in Oncobiologics, Inc., USA
5. Yale Cancer Center Joins OncLive's Strategic Alliance Partnership
6. Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory
7. Encina Wastewater Authority and Anaergia Announce Strategic Alliance to Produce Natural Fertilizer
8. BRANY and ACRES to Recognize Excellence at Clinical Trial Sites in Strategic Alliance
9. Agricultural Biotechnology: Transgenic Seeds/Crops and Biopesticides - Global Strategic Business Report - 2012-2018
10. Molecular Diagnostics - Global Strategic Business Report
11. Strategic Alliance With Dr. Narain Naidu and the Naidu Group of Companies Announced by ASEA, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... ... ACEA Biosciences, a pioneer in cell analysis instrumentation and the development of ... as the new Vice President of Global Clinical Development. With more than 15 ... will now team with Dr. Li Xu, Chief Medical Officer, and Dr. Xiao Xu, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... science and biotechnology companies today announced it named Joan Siefert Rose as ... out of Durham, NC and will begin work immediately. , Rose most recently ...
(Date:2/28/2017)... , Feb. 28, 2017 Sangamo ... genome editing, today reported its fourth quarter and ... "Early this year we rebranded our ... clinical development of genomic therapies using our industry ... gene regulation and cell therapy," said Sandy ...
(Date:2/27/2017)... 2017 A Europe-wide survey of institutes conducted ... animals in their research treat them with due care. The survey ... analysis of the results indicates that there is a strong commitment ... into practice the principles of the 3Rs (Refine, Reduce, Replace)  ... What are the ...
Breaking Biology Technology:
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):